|
1
|
Stein JP, Lieskovsky G, Cote R, et al:
Radical cystectomy in the treatment of invasive bladder cancer:
long-term results in 1,054 patients. J Clin Oncol. 19:666–675.
2001.PubMed/NCBI
|
|
2
|
Tsihlias J and Grossman HB: The utility of
fibrin/fibrinogen degradation products in superficial bladder
cancer. Urol Clin North Am. 27:39–46. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sutcliffe S and Colditz GA: Prostate
cancer: is it time to expand the research focus to early-life
exposures? Nat Rev Cancer. 13:208–518. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Troyer D: Emerging biomarkers in prostate
cancer. Aging Health. 2:579–588. 2006. View Article : Google Scholar
|
|
5
|
O’Brien T, Cranston D, Fuggle S, Bicknell
R and Harris AL: Different angiogenic pathways characterize
superficial and invasive bladder cancer. Cancer Res. 55:510–513.
1995.PubMed/NCBI
|
|
6
|
Nguyen M, Watanabe H, Budson AE, Richie JP
and Folkman J: Elevated levels of the angiogenic peptide basic
fibroblast growth factor in urine of bladder cancer patients. J
Natl Cancer Inst. 85:241–242. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chopin DK, Caruelle JP, Colombel M, et al:
Increased immunodetection of acidic fibroblast growth factor in
bladder cancer, detectable in urine. J Urol. 150:1126–1130.
1993.PubMed/NCBI
|
|
8
|
Campbell SC: Advances in angiogenesis
research: relevance to urological oncology. J Urol. 158:1663–1674.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He W, Cai Q, Sun F, et al: linc-UBC1
physically associates with polycomb repressive complex 2 (PRC2) and
acts as a negative prognostic factor for lymph node metastasis and
survival in bladder cancer. Biochim Biophys Acta. 1832:1528–1537.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fujita A, Sato JR, de Rodrigues LO,
Ferreira CE and Sogayar MC: Evaluating different methods of
microarray data normalization. BMC Bioinformatics. 7:4692006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gentleman R, Carey VJ, Huber W, Irizarry
RA and Dudoit S: Bioinformatics and Computational Biology Solutions
Using R and Bioconductor. 746718470. Springer; New York, NY: 2005,
pp. XIX
|
|
12
|
Eisen MB, Spellman PT, Brown PO and
Botstein D: Cluster analysis and display of genome-wide expression
patterns. Proc Natl Acad Sci USA. 95:14863–14868. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Saldanha AJ: Java Treeview - extensible
visualization of microarray data. Bioinformatics. 20:3246–3248.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Obayashi T, Hayashi S, Shibaoka M, Saeki
M, Ohta H and Kinoshita K: COXPRESdb: a database of coexpressed
gene networks in mammals. Nucleic Acids Res. 36:D77–D82. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sherman BT and Lempicki RA: Bioinformatics
enrichment tools: paths toward the comprehensive functional
analysis of large gene lists. Nucleic Acids Res. 37:1–13. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009.PubMed/NCBI
|
|
17
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ruzinova MB and Benezra R: Id proteins in
development, cell cycle and cancer. Trends Cell Biol. 13:410–418.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hartwell LH and Kastan MB: Cell cycle
control and cancer. Science. 266:1821–1828. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park MT and Lee SJ: Cell cycle and cancer.
J Biochem Mol Biol. 36:60–65. 2003. View Article : Google Scholar
|
|
21
|
Serrano M, Hannon GJ and Beach D: A new
regulatory motif in cell-cycle control causing specific inhibition
of cyclin D/CDK4. Nature. 366:704–707. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Takuwa N and Takuwa Y: Regulation of cell
cycle molecules by the Ras effector system. Mol Cell Endocrinol.
177:25–33. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wei Y, Chen YH, Li LY, et al:
CDK1-dependent phosphorylation of EZH2 suppresses methylation of
H3K27 and promotes osteogenic differentiation of human mesenchymal
stem cells. Nat Cell Biol. 13:87–94. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Malumbres M and Barbacid M: To cycle or
not to cycle: a critical decision in cancer. Nat Rev Cancer.
1:222–231. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tetsu O and McCormick F: Beta-catenin
regulates expression of cyclin D1 in colon carcinoma cells. Nature.
398:422–426. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tetsu O and McCormick F: Proliferation of
cancer cells despite CDK2 inhibition. Cancer cell. 3:233–245. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sherr CJ and Roberts JM: Living with or
without cyclins and cyclin-dependent kinases. Genes Dev.
18:2699–2711. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
LaBaer J, Garrett MD, Stevenson LF, et al:
New functional activities for the p21 family of CDK inhibitors.
Genes Dev. 11:847–862. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cheng M, Olivier P, Diehl JA, et al: The
p21(Cip1) and p27(Kip1) CDK ‘inhibitors’ are essential activators
of cyclin D-dependent kinases in murine fibroblasts. EMBO J.
18:1571–1583. 1999.
|
|
30
|
Dunn KL, Espino PS, Drobic B, et al: The
Ras-MAPK signal transduction pathway, cancer and chromatin
remodeling. Biochem Cell Biol. 83:1–14. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dangle PP, Zaharieva B, Jia H and Pohar
KS: Ras-MAPK pathway as a therapeutic target in cancer - emphasis
on bladder cancer. Recent Pat Anticancer Drug Discov. 4:125–136.
2009. View Article : Google Scholar : PubMed/NCBI
|
